Cargando…
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group Ltd.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652813/ https://www.ncbi.nlm.nih.gov/pubmed/37973164 http://dx.doi.org/10.1136/bmj.p2665 |
| _version_ | 1785147738984284160 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10652813 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | BMJ Publishing Group Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106528132023-11-16 Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial BMJ Corrections BMJ Publishing Group Ltd. 2023-11-16 /pmc/articles/PMC10652813/ /pubmed/37973164 http://dx.doi.org/10.1136/bmj.p2665 Text en © Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Corrections Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial |
| title | Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial |
| title_full | Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial |
| title_fullStr | Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial |
| title_full_unstemmed | Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial |
| title_short | Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial |
| title_sort | pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with her2 positive metastatic breast cancer (phila): randomised, double blind, multicentre, phase 3 trial |
| topic | Corrections |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652813/ https://www.ncbi.nlm.nih.gov/pubmed/37973164 http://dx.doi.org/10.1136/bmj.p2665 |